USANA Health Sciences (NYSE:USNA) Posts Earnings Results, Misses Estimates By $0.22 EPS

USANA Health Sciences (NYSE:USNA) announced its earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.22), FiscalAI reports. The firm had revenue of $205.89 million during the quarter, compared to analysts’ expectations of $217.42 million. USANA Health Sciences had a negative net margin of 2.34% and a positive return on equity of 3.55%.

USANA Health Sciences Trading Down 3.8%

USNA stock opened at $14.31 on Thursday. The firm has a 50 day simple moving average of $14.61 and a 200-day simple moving average of $18.03. The company has a market capitalization of $264.45 million, a P/E ratio of -12.44, a PEG ratio of 1.63 and a beta of 0.66. USANA Health Sciences has a twelve month low of $12.57 and a twelve month high of $23.59.

Key Headlines Impacting USANA Health Sciences

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: The third-quarter net loss narrowed to $5.6 million from $6.5 million a year earlier, while adjusted diluted loss per share improved to $0.11 from $0.15. USANA Health Sciences Reports Third Quarter 2026 Results
• Negative Sentiment: Revenue fell 4% year over year to $206 million, below analysts’ $217.42 million estimate. Adjusted EBITDA also declined to $12.1 million from $13.8 million, and the company lowered its fiscal 2026 outlook—raising concerns about near-term demand and profitability. USANA’s Q3 Loss Narrows, Sales Decline 4%; FY26 Outlook Lowered
• Negative Sentiment: Sidoti cut its FY2027 EPS estimate to $1.59 from $1.77 and lowered forecasts for Q1, Q2 and Q3 2027. Its Q4 2026 estimate rose slightly, to $0.12 from $0.11, but the broader revisions point to weaker expected earnings. USANA Health Sciences analyst coverage

Wall Street Analyst Weigh In

A number of brokerages have commented on USNA. Zacks Research upgraded shares of USANA Health Sciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, September 21st. Finally, Wall Street Zen lowered USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce”.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.